Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
- 1 February 1987
- Vol. 28 (2) , 113-116
- https://doi.org/10.1136/gut.28.2.113
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Lysis of primary hepatic tumours by lymphokine activated killer cells.Gut, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984
- Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cellsCancer, 1984
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donorsInternational Journal of Cancer, 1972